Enterome teams up with AbbVie to create molecular Dx for Crohn's disease

French startup Enterome Bioscience has been generating some upward momentum lately, inking deals and raking in funds to develop its personalized microbiome tests. Now, the company is teaming up with Big Pharma heavyweight AbbVie ($ABBV) to create molecular diagnostic tools that will help find the best therapies for patients with Crohn's disease. "This development partnership, along with the others that we have signed in recent months, demonstrates a strong and growing interest from a broad range of healthcare companies in our microbiome-based approach to disease monitoring and management," CEO Pierre Belichard said in a statement. Release (PDF)

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.